Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2011-3-11
pubmed:abstractText
Osteopontin has been implicated in various inflammatory diseases including rheumatoid arthritis, multiple sclerosis, Crohn's disease, and fulminant hepatitis. Increased expression of osteopontin has been detected in pathological foci of these diseases. RA and fulminant hepatitis have been successfully treated by administration of neutralizing anti-osteopontin antibody in mice. However, rodent antibodies are highly immunogenic in humans and therefore limited in their clinical application. Here, a murine monoclonal antibody 23C3 against human osteopontin, was humanized by complementarity-determining region grafting method based on computer-assisted molecular modeling. The humanized version of 23C3, denoted as Hu23C3, was shown to possess affinity comparable to that of its parental antibody. Hu23C3 could also inhibit monocyte migration in response to osteopontin in vitro. Furthermore, in vivo data showed that Hu23C3 significantly protects mice from Concanavalin A (Con A) induced-liver injury in association with the reduction of transaminase activities and improvement of liver injury. Mechanistic studies demonstrated that Hu23C3 inhibited T and NKT cell infiltration, and activation of nuclear factor ?B (NF-?B) in the liver, resulting in reduction of TNF-? and IFN-? production. Thus, our data strongly support that the humanized anti-osteopontin antibody, Hu23C3, may have a potential for the treatment of T cell mediated-hepatitis in human.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1879-0712
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 Elsevier B.V. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
657
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
144-51
pubmed:meshHeading
pubmed-meshheading:21300057-Amino Acid Sequence, pubmed-meshheading:21300057-Animals, pubmed-meshheading:21300057-Antibodies, Monoclonal, pubmed-meshheading:21300057-Cell Movement, pubmed-meshheading:21300057-Concanavalin A, pubmed-meshheading:21300057-Drug-Induced Liver Injury, pubmed-meshheading:21300057-Hepatitis, pubmed-meshheading:21300057-Humans, pubmed-meshheading:21300057-Immunoglobulin Variable Region, pubmed-meshheading:21300057-Interferon-gamma, pubmed-meshheading:21300057-Lymphocytes, pubmed-meshheading:21300057-Male, pubmed-meshheading:21300057-Mice, pubmed-meshheading:21300057-Mice, Inbred C57BL, pubmed-meshheading:21300057-Models, Molecular, pubmed-meshheading:21300057-Molecular Sequence Data, pubmed-meshheading:21300057-Monocytes, pubmed-meshheading:21300057-NF-kappa B, pubmed-meshheading:21300057-Osteopontin, pubmed-meshheading:21300057-Protein Conformation, pubmed-meshheading:21300057-Tumor Necrosis Factor-alpha
pubmed:year
2011
pubmed:articleTitle
A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice.
pubmed:affiliation
International Joint Cancer Institute, The Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, People's Republic of China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't